Trial ID or NCT#



not recruiting iconNOT RECRUITING


This is a multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of "definite NASH" with fibrosis (excluding cirrhosis) as determined by the central histopathologist. Upon successful screening, subjects will be randomized to receive either emricasan 50 mg BID or emricasan 5 mg BID or matching placebo BID.

Official Title

A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


W. Ray Kim, MD
W. Ray Kim, MD
Transplant hepatologist, Hepatologist, Gastroenterologist
Professor of Medicine (Gastroenterology and Hepatology) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.


Alexis Touros
(650) 721-4285